Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

A method of treating epilepsy in a living animal comprising the step of administering to the living animal a therapeutically effective amount of a compound selected from those of formula 1,

• wherein
• R and R1-R5 are each independently selected from C1-C6 alkyl groups, C2-C5 alkenyl groups, C2-C6 alkynyl groups, C6-C12 aryl-C1-C4 alkyl groups, and C6-C12 aryl groups, wherein R and R2-R5 may also be hydrogen atoms, or R and R1 together represent a C3-C5 alkylene or alkenylene group, R2-R5 being as defined above;
• Y is CH;
• and
• Z represents a valence bond;
• and optical isomers and pharmaceutically-acceptable acid and base addition salts thereof.

A pharmaceutical composition consisting of a compound selected from those of formula 1,

• wherein
• R and R1-R5 are each independently selected from C1-C6 alkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, C6-C12 aryl-C1-C4 alkyl groups, and C6-C12 aryl groups, wherein R and R2-R5 may also be hydrogen atoms, with the proviso that at least one of R2 and R3 and at least one of R4 and R5 are other than hydrogen, or R and R1 together represent a C3-C5 alkylene or alkenylene group, R2-R5 being as defined above;
• Y is CH;
• and
• Z represents a valence bond;
• and optical isomers and pharmaceutically-acceptable acid and base addition salts thereof in combincation with one or more pharmaceutically-acceptable diluents, excipients, or carrier.